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PDifferences in Restenosis Rate
With Different Drug-Eluting Stents in
Patients With and Without Diabetes Mellitus
A Report From the SCAAR (Swedish Angiography and
Angioplasty Registry)
Ole Fröbert, MD, PHD,* Bo Lagerqvist, MD, PHD,† Jörg Carlsson, MD, PHD,‡
Johan Lindbäck, MS,§ Ulf Stenestrand, MD, PHD, Stefan K. James, MD, PHD†
Örebro, Uppsala, Kalmar, and Linköping, Sweden
Objectives Our aim was to evaluate restenosis rate of drug-eluting stents (DES) in patients with and without diabetes melli-
tus (DM) in a real-world setting.
Background DES seem less effective in patients with DM.
Methods The SCAAR (Swedish Coronary Angiography and Angioplasty Registry) includes all patients undergoing percutaneous
coronary intervention in Sweden. From April 1, 2004, to April 20, 2008, all restenoses detected at a subsequent
angiography and all DES types implanted at more than 500 occasions were assessed using Cox regression.
Results Four DES types qualified for inclusion. In total, 35,478 DES were implanted at 22,962 procedures in 19,004 pa-
tients and 1,807 restenoses were reported over a mean 29 months follow-up. In the entire population, the reste-
nosis rate per stent was 3.5% after 1 year and 4.9% after 2 years. The adjusted risk of restenosis was higher in
patients with DM compared with that in patients without DM (relative risk [RR]: 1.23, 95% confidence interval
[CI]: 1.10 to 1.37). In patients with DM, restenosis was twice as frequent with the zotarolimus-eluting Endeavor
stent (Medtronic, Minneapolis, Minnesota) compared with that in the other DES types. The Endeavor stent and
the sirolimus-eluting Cypher stent (Cordis, Johnson & Johnson, Miami, Florida) had higher restenosis rates in pa-
tients with DM compared with those in patients without DM (RR: 1.77, 95% CI: 1.29 to 2.43 and RR: 1.25, 95%
CI: 1.04 to 1.51). Restenosis rate with the paclitaxel-eluting Taxus Express and Liberté (Boston Scientific, Natick,
Massachusetts) stents was unrelated to DM. Mortality did not differ between different DES.
Conclusions Restenosis rate with DES was higher in patients with DM compared with that in patients without DM. There
seem to be important differences between different brands of DES. (J Am Coll Cardiol 2009;53:1660–7)
© 2009 by the American College of Cardiology Foundation












toronary artery stenting in patients with diabetes mellitus
DM) is associated with higher rates of restenosis and repeat
evascularization compared with those seen in patients
ithout DM (1,2). Randomized trials (3,4) and results from
egistries (5) seem to favor the use of drug-eluting stents
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wedish Association of Local Authorities and Regions and the Swedish Heart-Lung
oundation (to SCAAR and the Uppsala Clinical Research Center) (all Stockholm,
weden).w
Manuscript received September 23, 2008; revised manuscript received January 22,
009, accepted January 27, 2009.DES) over bare-metal stents (BMS) for better clinical and
ngiographic outcome. Most data on patients with DM and
ES are available for the sirolimus-eluting Cypher stent
Cordis, Johnson & Johnson, Miami, Florida) and the
aclitaxel-eluting Taxus stent (Boston Scientific, Natick,
assachusetts) (3,5–9). However, with more players on the
arket for DES, other stent platforms, drugs, and polymers
re introduced. The zotarolimus-eluting Endeavor stent
Medtronic, Minneapolis, Minnesota) was approved by the
.S. Food and Drug Administration for coronary revascu-
arization in the U.S. in early 2008 while this stent has
lready been used in other countries since 2003 (10).
It is important to look at real-world data when evaluating
reatment strategies; both because “off-label” use of DES is
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May 5, 2009:1660–7 Diabetes and Restenosis Rateandomized head-to-head comparisons of all different DES
ypes are unrealistic. We determined that the evaluation of
arge clinical registries might provide useful information
oncerning the long-term efficacy and safety of DES.
herefore, we evaluated the restenosis rate in all patients,
tratified for DM status, who underwent stent implantation
n Sweden from April 2004 to April 2008, as recorded in the
CAAR (Swedish Coronary Angiography and Angioplasty
egistry).
ethods
tudy population. Our study included all patients in Swe-
en who had received coronary stents from April 1, 2004, to
pril 20, 2008. The analyses were based on the type of stent
mplanted at the first recorded procedure. Patients who
eceived at least 1 DES were included in the analysis,
egardless of whether they had received another type of stent
t any time. In order to be included in this analysis only
ES types implanted on more than 500 occasions during
he study period were assessed. Data from 1 small center
as excluded from the analysis due to incomplete registra-
ion of coronary angiographies.
he SCAAR data. The SCAAR holds data on consecutive
atients from all 26 centers that perform coronary angiog-
aphy and percutaneous coronary intervention (PCI) in
weden. The registry is sponsored by the Swedish Health
uthorities and is independent of commercial funding. The
echnology is developed and administered by the Uppsala
linical Research Center. Since 2001, SCAAR has been
nternet-based, with recording of data online through an
nternet interface in the catheterization laboratory; data are
ransferred in an encrypted format to a central server at the
ppsala Clinical Research Center. All consecutive patients
ndergoing coronary angiography or PCI are included.
nformation with respect to restenosis has been registered
or patients undergoing any subsequent coronary angiogra-
hy for a clinical reason since the beginning of 2004.
ecause of the nature of this study using real-life registry
ata, all restenoses identified by repeat angiography did not
ead to repeat revascularization. Accordingly, in this study,
estenosis is not identical to “target lesion revascularization”
s defined in other publications. Throughout the study we
se the terminology “restenosis” defined as angiographically
ignificant restenosis detected at any repeat angiography
ecause of ischemic symptoms. The Internet-based system
rovides each center with immediate and continuous feed-
ack on processes and quality-of-care measures. Monitoring
nd verification of registry data have been performed in all
ospitals since 2001 by comparing 50 entered variables in 20
andomly selected interventions per hospital and year with
he patients’ hospital records. The overall correspondence of
ata during the study period was 95.2%.
tatistical analysis. We summarized baseline characteris-
ics of the patients with means and standard deviations for
ontinuous variables and percentages for discrete variables. rumulative event rates were es-
imated by the Kaplan-Meier
ethod. The primary objective
as to evaluate restenosis rates
fter the implantation of DES.
he primary end point was clin-
cally driven restenosis rate. The
econdary end point was death.
he cumulative adjusted relative
isk (RR) of the primary end
oint was calculated using Cox
roportional hazard method. All
actors in Tables 1 and 2 were forced into the model
ogether with information on treating hospital, year of
rocedure, and complete revascularization. Diabetes was
ichotomized to yes/no as the variable diabetes treatment
as not known for the first part of the study period.
Statistical interaction was tested by introducing the in-
eraction terms diabetes*stent name and diameter of
tent*stent name in the used model. Difference in adjusted
ortality between the different stents was analyzed using
he same model in a subgroup of patients with only 1 stent
DES) implanted where only the first PCI during the study
eriod was included. Vital status and date of death was
btained from the National Population Registry until April
5, 2008. Hospitalizations due to myocardial infarction
ere available until December 31, 2007, from the Swedish
egistry of inhospital diagnosis. The merging of the regis-
ries was performed by the Epidemiologic Centre of the
wedish National Board of Health and Welfare and ap-
roved by the local ethics committee at the Uppsala Uni-
ersity. In the majority of analyses the statistical unit was
tent and not the patient. However, in the subgroup
nalyses of mortality and rehospitalizations with a diagnosis
f myocardial infarction the statistical unit was patient. And
ere only data from the first PCI during the study period in
atients with only 1 stent were analyzed. All reported
values are 2-sided. All analyses were performed with the
se of SPSS statistical software (version 15.0, SPSS Inc.,
hicago, Illinois).
esults
uring the study period, 35,478 DES were implanted at
2,962 procedures in 19,004 patients. Baseline characteris-
ics are listed in Table 1. Patients with DM compared with
atients without DM were more often women, less often
mokers, and had more often hyperlipidemia, hypertension,
nd previous coronary artery disease. Angiographic data are
hown in Table 2. Minor, but significant, differences were
ound with respect to multivessel disease, lesion type,
estenotic lesion, chronic total occlusion, and stent diame-
er. Follow-up time was 29.1  11.1 months.
Restenosis was reported in 3.5% of all stents after 1 year
nd in 4.9% of all stents 2 years after implantation. The
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
DM  diabetes mellitus
PCI  percutaneous
coronary intervention
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Diabetes and Restenosis Rate May 5, 2009:1660–7.9% for Cypher stents, 3.7% and 5.1% for Taxus Express
tents, 3.2% and 4.1% for Taxus Liberté stents, and 4.9% and
.5% for Endeavor stents. There were considerable differences
etween the different stents in both patients with DM and in
atients without DM (Fig. 1). In patients with DM the
djusted RR of restenosis was twice as high with the Endeavor
tent compared with the other types of DES (Table 3). There
ere no statistically significant differences between other
tent types in patients with DM. In patients without DM
here were smaller but significant differences in restenosis
ate; with the Endeavor and the Taxus Express stents the
djusted restenosis rates were 20% to 30% higher than with
he Cypher and Taxus Liberté stents. It is also noteworthy
hat in patients without DM the adjusted risk of restenosis
as significantly higher with the Taxus Express than with
he Taxus Liberté stent (Table 3).
The adjusted risk of restenosis was higher in patients with
M than in patients without DM (RR: 1.23, 95% confi-
ence interval [CI]: 1.10 to 1.37). This difference was also
ound for the zotarolimus-eluting Endeavor stent (Fig. 2A)
nd the sirolimus-eluting Cypher stent (Fig. 2B) with
igher rates of restenosis in patients with DM compared
ith those in patients without DM (RR: 1.77, 95% CI: 1.29
aseline Characteristics












n 2,615 2,182 2,553 88
Age, yrs, mean SD 65.1 10.4 65.6 9.9 66.6 9.8 66.7




896 (34.3) 732 (33.5) 851 (33.4) 280 (
Unstable coronary
artery disease
1,413 (54.0) 1,157 (53.0) 1,338 (52.4) 509 (
STEMI 262 (10.0) 269 (12.3) 301 (11.8) 80 (
Other 44 (1.7) 24 (1.1) 62 (2.4) 12 (
Diabetes mellitus, n (%)
Insulin treatment 1,182 (45.2) 698 (32.0) 1,236 (48.4) 412 (
Noninsulin treatment 1,186 (54.4) 742 (34.0) 1,317 (51.6) 469 (
Unknown treatment 247 (9.4) 742 (34.0) 0 0
Smoking status, n (%)
Current smoker 337 (12.9) 325 (14.9) 337 (13.2) 148 (
Former smoker 990 (37.9) 772 (35.4) 1,002 (39.2) 319 (
Never smoked 1,124 (43.0) 907 (41.6) 1,071 (42.0) 344 (
Unknown 164 (6.3) 177 (8.1) 143 (5.6) 70 (
Hyperlipidemia, n (%) 1,941 (74.2) 1,544 (70.8) 1,866 (73.1) 694 (
Hypertension, n (%) 1,745 (66.7) 1,461 (67.0) 1,907 (74.7) 619 (
Previous myocardial
infarction, n (%)
1,105 (42.3) 928 (42.5) 1,042 (40.8) 384 (
Previous coronary
angioplasty, n (%)
950 (36.3) 657 (30.1) 892 (34.9) 296 (
Previous CABG, n (%) 435 (16.6) 354 (16.2) 451 (17.7) 210 (
ll variables differed statistically significantly between the different stents (p 0.001) except indic
ypass grafting (CABG) (p  0.095) in the nondiabetes mellitus group.
STEMI  ST-segment elevation myocardial infarction.o 2.43 and RR: 1.25, 95% CI: 1.04 to 1.51, respectively). cith the paclitaxel-eluting Taxus Express stent (Fig. 2C)
he incidence of restenosis was similar in patients with DM
ompared with that in patients without DM (RR: 1.10, 95%
I: 0.91 to 1.34) and with Taxus Liberté stent (Fig. 2D)
here was a trend to a higher rate of restenosis in patients
ith DM (RR: 1.19, 95% CI: 0.94 to 1.49). The therapeutic
ecision in the 1,370 cases in which a restenosis was
etected was repeat PCI in 80.1%, coronary artery bypass
rafting in 9.4%, and no coronary intervention in 10.4%.
Information about diabetes treatment has been registered
n the SCAAR database from May 1, 2005 and onward.
rom this date and to the end of the study period, 26,020
tents were implanted resulting in 1,214 restenoses. There
as no statistically significant difference in restenosis rate in
tents placed in patients with insulin-treated DM (n 
,018) compared with that in stents placed in patients with
oninsulin-treated DM (n  3,061) (RR: 0.84, 95% CI:
.67 to 1.04). Adjusted risks of restenosis were more than
oubled (significant) in Endeavor compared with those in
axus Liberté and compared with those in Taxus Express
tents both in insulin-treated and in noninsulin-treated
atients. Also in comparison with the Cypher stent the















8,231 8,667 7,447 8,483 2,650
65.9 10.1 65.1 10.8 65.2 10.8 66.2 10.6 65.7 10.9
2,579 (31.4) 2,283 (26.3) 1,880 (25.2) 2,253 (26.6) 691 (26.1)
2,760 (33.5) 3,047 (35.2) 2,460 (33.0) 2,835 (33.4) 883 (33.3)
4,417 (53.7) 4,315 (49.8) 3,795 (51.0) 4,115 (48.5) 1,395 (52.6)
912 (11.1) 1,176 (13.6) 1,096 (14.7) 1,361 (16.0) 333 (12.6)




1,147 (13.9) 1,543 (17.8) 1,407 (18.9) 1,518 (17.9) 467 (17.6)
3,084 (37.5) 3,208 (37.0) 2,534 (34.0) 3,070 (36.2) 936 (35.3)
3,446 (41.9) 3,523 (40.6) 3,078 (41.3) 3,583 (42.2) 1,094 (41.3)
554 (6.7) 393 (4.5) 432 (5.8) 312 (3.7) 153 (5.8)
6,045 (73.4) 5,206 (60.1) 4,138 (55.6) 4,792 (56.5) 1,632 (61.6)
5,733 (69.7) 4,120 (47.5) 3,319 (44.6) 4,358 (51.4) 1,305 (49.2)
3,459 (42.0) 2,991 (34.5) 2,486 (33.4) 2,714 (32.0) 902 (34.0)
2,795 (34.0) 2,791 (32.2) 1,877 (25.3) 2,493 (29.4) 750 (28.3)
1,450 (17.6) 917 (10.6) 804 (10.8) 897 (10.6) 333 (12.6)




















ation (pant) for Endeavor in noninsulin-treated patients. Endeavor
Angiographic and Lesion Characteristics
Table 2 Angiographic and Lesion Characteristics



























Number of stents per
procedure, mean SD
1.69 0.96 1.71 0.94 1.74 1.00 1.74 0.98 1.72 0.96 1.70 0.94 1.70 0.96 1.78 1.02 1.73 0.94 1.72 0.97
Findings on angiography, n (%)
Not significant 13 (0.5) 10 (0.5) 12 (0.5) 4 (0.5) 39 (0.5) 27 (0.3) 28 (0.3) 47 (0.6) 11 (0.4) 109 (0.4)
1-vessel disease 786 (30.1) 667 (30.6) 760 (29.8) 245 (27.8) 2,458 (29.9) 3,501 (40.4) 3,978 (40.0) 3,404 (40.0) 1,012 (38.2) 10,895 (40.0)
2-vessel disease 946 (36.2) 741 (34.0) 882 (34.5) 279 (31.7) 2,848 (34.6) 2,989 (34.4) 2,432 (32.7) 2,816 (33.2) 930 (35.1) 9,167 (33.6)
3-vessel disease 695 (26.6) 607 (27.8) 683 (26.8) 283 (32.1) 2,268 (27.6) 1,625 (18.7) 1,448 (19.4) 1,652 (19.5) 530 (20.0) 5,255 (19.3)
Left main coronary artery
disease
129 (4.9) 131 (6.0) 193 (7.6) 58 (6.6) 511 (6.2) 391 (4.5) 451 (6.1) 479 (5.6) 129 (4.9) 1,450 (5.3)
Stent diameter, mean SD 2.81 0.39 2.87 0.47 2.85 0.46 2.90 0.47 2.85 0.44 2.82 0.41 2.91 0.49 2.87 0.46 2.89 0.45 2.87 0.45
Stent length, mean SD 19.7 7.3 18.1 6.4 18.0 6.5 18.1 6.5 18.6 6.8 19.7 7.4 18.2 6.6 18.3 6.5 18.6 6.8 18.7 6.9
Restenotic lesion, n (%) 335 (12.8) 188 (8.6) 228 (8.9) 69 (7.8) 820 (10.0) 1,058 (12.2) 533 (7.2) 640 (7.5) 207 (7.8) 2,438 (8.9)
Chronic total occlusion, n (%) 128 (4.9) 98 (4.5) 139 (5.4) 40 (4.5) 405 (4.9) 602 (6.9) 311 (4.2) 524 (6.2) 155 (5.8) 1,592 (5.8)
Treated vessel, n (%)
Right coronary artery 666 (25.5) 602 (27.6) 664 (26.0) 221 (25.1) 2,153 (26.2) 2,102 (24.3) 1,729 (23.2) 2,155 (25.4) 691 (26.1) 6,677 (24.5)
Left main coronary artery 45 (1.7) 59 (2.7) 63 (2.5) 20 (2.3) 187 (2.3) 136 (1.6) 214 (2.9) 174 (2.1) 50 (1.9) 574 (2.1)
Left anterior descending
coronary artery
1,205 (46.1) 906 (41.5) 1,027 (40.2) 347 (39.4) 3,485 (42.3) 4,330 (50.0) 3,690 (49.6) 3,922 (46.2) 1,216 (45.9) 13,158 (48.3)
Left circumflex coronary
artery
606 (23.2) 505 (23.1) 667 (26.1) 226 (25.7) 2,004 (20.3) 1,885 (21.7) 1,550 (20.8) 1,987 (23.5) 610 (23.0) 6,032 (22.1)
CABG 93 (3.5) 110 (5.1) 132 (5.2) 67 (7.6) 402 (4.9) 214 (2.4) 264 (3.6) 245 (2.9) 83 (3.1) 806 (3.0)
Lesion classification, n (%)
Type A 279 (10.7) 205 (9.4) 267 (10.5) 108 (12.3) 859 (10.4) 910 (10.5) 711 (9.5) 940 (11.1) 303 (11.4) 2,864 (10.5)
Type B1 794 (30.4) 658 (30.2) 857 (33.6) 270 (30.6) 2,579 (31.3) 2,324 (26.8) 2,134 (28.7) 2,892 (34.1) 872 (32.9) 8,222 (30.2)
Type B2 710 (27.2) 602 (27.6) 770 (30.2) 261 (29.6) 2,343 (28.5) 2,623 (30.3) 2,060 (27.7) 2,498 (29.4) 823 (31.1) 8,004 (29.4)
Type C 716 (27.4) 512 (23.5) 657 (25.7) 240 (27.2) 2,125 (25.8) 2,408 (27.8) 1,810 (24.3) 2,129 (25.1) 641 (24.2) 6,988 (25.6)
Unknown 116 (4.4) 205 (9.4) 2 (0.1) 2 (0.2) 325 (3.9) 402 (4.6) 732 (9.8) 24 (0.3) 11 (0.4) 1,169 (4.3)
All variables differed statistically significant between the different stents (p  0.001) except for number of stents per procedure (p  0.456) and chronic total occlusion (p  0.493) in the group of patients with diabetes mellitus.
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Diabetes and Restenosis Rate May 5, 2009:1660–7ompared with Cypher in insulin-treated patients demon-
trated an insignificant trend (RR: 1.55, 95% CI: 0.98 to 2.47).
In the statistical model, stent diameter was independently
ssociated with a lower risk of restenosis (RR: 0.58, 95% CI:
.46 to 0.74). Stent length, assessed as a 1-mm increase, was
ot associated with an increased risk of restenosis (RR: 1.01,
Figure 1 Estimated Cumulative Event Rates
A shows propensity score adjusted probability of restenosis in patients with
diabetes mellitus and B shows the same for patients without diabetes melli-
tus. Risk ratios (with 95% confidence intervals) are for occurrence of resteno-
sis with 1 stent type compared with another stent type. PCI  percutaneous
coronary intervention.5% CI: 0.99 to 1.01). Stents placed in chronic total Rcclusions had a higher risk of restenosis than stents placed
n nonoccluded lesions (RR: 1.29, 95% CI: 1.06 to 1.57).
here was a statistically significant interaction between type
f DES and diabetes status (p  0.006) but no statistically
ignificant interaction between type of DES and stent
iameter. In a subgroup analysis the material was divided
nto 2 groups of equal size with a cutoff at the median stent
iameter. In patients with DM the higher risk of restenosis
emained with Endeavor stents compared with that in all
he other DES in the group of smaller stents (2.75 mm)
s well as in the group of stents with larger diameter (2.75
m) (detailed results not shown).
Of all patients, 3.9% died within 1 year after stent
mplantation and 6.0% died within 2 years. The incidence of
eported myocardial infarctions was 7.3% and 10.2% after 1
nd 2 years, respectively. Stent-specific information on
eath and myocardial infarction is reported for patients in
hom only 1 DES was implanted. Definite information
egarding death was available in 9,860 patients (52% of all
atients) of whom 674 died during the follow-up period.
nformation regarding rehospitalizations to Swedish hospi-
als with a diagnosis of myocardial infarction was available
n 9,273 patients (49% of all) of whom 925 had a myocardial
nfarction before the end of 2007. Mortality (Fig. 3) or
yocardial infarction rates did not differ between different
ES (p  0.933 and p  0.793, respectively).
iscussion
he main findings of this national registry study on DES in
atients with DM are: 1) The rate of restenosis with DES
djusted RR of Restenosisairwise Comparison Between Stents
Table 3 Adjusted RR of RestenosisPairwise Comparison Between Stents
RR 95% Confidence Interval
Patients with diabetes
Endeavor vs. Taxus Liberté 2.18 1.55–3.07
Endeavor vs. Taxus Express 2.08 1.43–3.00
Endeavor vs. Cypher 1.99 1.43–2.77
Taxus Express vs. Taxus Liberté 1.05 0.76–1.44
Cypher vs. Taxus Liberté 1.10 0.82–1.46
Cypher vs. Taxus Express 1.04 0.80–1.36
Patients without diabetes
Endeavor vs. Taxus Liberté 1.31 1.03–1.67
Endeavor vs. Taxus Express 0.99 0.77–1.28
Endeavor vs. Cypher 1.23 0.97–1.55
Taxus Express vs. Taxus Liberté 1.32 1.10–1.60
Cypher vs. Taxus Liberté 1.07 0.90–1.28
Cypher vs. Taxus Express 0.81 0.68–0.95
All patients
Endeavor vs. Taxus Liberté 1.55 1.28–1.89
Endeavor vs. Taxus Express 1.26 1.03–1.56
Endeavor vs. Cypher 1.45 1.20–1.76
Taxus Express vs. Taxus Liberté 1.23 1.04–1.45
Cypher vs. Taxus Liberté 1.07 0.92–1.81
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May 5, 2009:1660–7 Diabetes and Restenosis Rateas higher in patients with DM compared with patients
ithout DM. 2) There seems to be significant differences in
estenosis rate between different stents. The zotarolimus-
luting Endeavor stent was associated with a restenosis rate
n patients with DM twice the rate in patients without DM.
he sirolimus-eluting Cypher stent had a 30% increased
Figure 2 Estimated Cumulative Rates of Restenosis With Resp
Estimated cumulative event rates in patients with diabetes mellitus (DM) and pati
(95% confidence intervals [CIs]) are for occurrence of restenosis in patients with Destenosis risk in patients with DM. 3) There were no sifferences in mortality between patients with DM receiving
ifferent DES.
Experiences from many previous randomized stent trials
ave shown that patients with DM respond with less favorable
utcome than do patients without DM. Patients with DM
ave a higher risk of death and higher restenosis rates after
o Stent Type
ithout DM for the 4 different stent types (A to D) analyzed. Risk ratios (RRs)
pared with patients without DM. PCI  percutaneous coronary intervention.ect t
ents w
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Diabetes and Restenosis Rate May 5, 2009:1660–7he advantage of DES on restenosis compared with BMS is
ot as apparent in patients with DM (7).
One of the problems in acquiring data on patients with
M after stenting is to achieve high enough numbers of
atients in clinical trials. While the effect of DES compared
ith that of BMS in patients with DM has been investi-
ated in some clinical trials (3,4,11) only few dedicated
tudies comparing different DES in patients with DM are
vailable. The ISAR-DIABETES (Paclitaxel-Eluting Stent
ersus Sirolimus-Eluting Stent for the Prevention of Re-
tenosis in Diabetic Patients With Coronary Artery Dis-
ase) study randomized 125 patients with DM to the
irolimus-eluting Cypher stent and 125 patients with DM
o the paclitaxel-eluting Taxus stent. Target lesion revascu-
arization at 9 months was 6.4% in the Cypher arm versus
2.0% in Taxus (p 0.13) but the trial was not powered for
linical restenosis (8). In the DM subgroup of the SIRTAX
Sirolimus-Eluting Stent Compared With Paclitaxel-
luting Stent for Coronary Revascularization) trial at 2
ears these numbers were 7.4% and 17.2% (p 0.03) (7). In
n elegant head-to-head comparison, patients with DM and
-vessel coronary artery disease were randomized to Cypher
tent in 1 vessel and Taxus stent in the other (6). Late loss
t 8 months was 0.26 mm in Cypher lesions versus 0.50 mm
n Taxus lesions (p  0.01). However, results from smaller
egistries contrast the above findings. Three different reports
n, respectively, 1,320, 293, and 260 consecutive patients
Figure 3 Adjusted Risk of Death With Respect to Stent Type
Adjusted risk of death with the 4 different drug-eluting stents (DES) in a sub-
population of patients who only had 1 DES implanted. PCI  percutaneous cor-
onary intervention.ith DM receiving sirolimus- or paclitaxel-eluting stents tound no statistically significant differences in death, major
dverse cardiac events, or revascularization between stent
ypes (9,12,13). In line with these findings and in contrast to
he clinical studies cited above it is evident that the Cypher
tent performs equivalent compared with Taxus stents in
linically driven restenosis in patients with DM in the
resent study. In a recent meta-analysis incorporating most
vailable randomized clinical trials and registry data of more
han 11,000 patients with DM receiving sirolimus- or
aclitaxel-eluting stents, revascularization and major adverse
ardiac events estimates were similar (14). However,
ollow-up time in all the studies included in this meta-
nalysis ranged between 6 to 12 months thus leaving out
ong-time effects (14).
Almost all comparative data on DES in patients with
M are available only for Cypher and Taxus stents. With
ore than 20 different DES having received a CE mark
pproval, randomized head-to-head comparisons of all stent
ypes are unrealistic. This study represents the first large-
cale evaluation of the zotarolimus-eluting Endeavor stent
n patients with DM and underlines the importance of
ontinuous registry monitoring of new coronary stents. We
ound the Endeavor stent to be associated with restenosis
wice the rate in patients with DM compared with that in
atients without DM. This alarming finding should of
ourse be verified in a prospective randomized clinical trial
efore any conclusion can be drawn and the result of the
ROTECT (Prophylaxis of Thromboembolism in Critical
are) trial including 8,800 patients in a comparison of
ypher and Endeavor stents is awaited. However, of notice,
n the 1,197 patients Endeavor II trial (comparing a Driver
MS with the Endeavor DES) among patients who re-
eived an Endeavor stent, in-stent restenosis after 8 months
as 7.8% for patients without DM, 16.7% for noninsulin-
ependent DM patients, and 20.0% for insulin-dependent
atients (15).
Differences in findings between clinical trial and registry
tudies underline that some surrogate end points used in
linical trials, such as late loss, have shortcomings in
omparison with real-world information. An advantage of
he present registry study compared with that of clinical
rials is that advanced age and stenting of left main coronary
rtery and stenting in acute myocardial infarction were
ncluded in contrast to what is often the case in trials.
egistry data cannot substitute randomized clinical trials.
owever, the SCAAR is particularly valuable because it
rovides PCI data from an entire country with complete and
ontinuous registration of all deaths and all repeat PCIs. To
ur knowledge the present report is the largest on DES and
estenosis in patients with DM. It is also one of the first
eports to include data on more than 2 different DES and
he follow-up time of almost two and one-half years is
onger than in most previous publications on restenosis
nd DM.
In order to look into explanations for our findings,
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May 5, 2009:1660–7 Diabetes and Restenosis Ratetudy release small amounts of pharmacological agents with
ntirestenosis properties at the implantation site. All 4
tents have polymer coating as a drug carrier in order to slow
he release of drug to prevent restenosis for as long a time as
ossible. A difference in the mechanism of action of
aclitaxel and sirolimus in diabetic patients has been hy-
othesized (14) but it is important to realize that not only
ype of drug and type of polymer contribute to restenosis. As
an be seen from the Taxus data in this study, despite the
ame polymer coating containing 1 g/mm2 of paclitaxel,
he Taxus Liberté stent with a flexible cell geometry, thin
truts, and uniform cell distribution had a lower restenosis
ate at 2 years compared with the older, more rigid Taxus
xpress stent with a different geometry.
tudy limitations. Inherent limitations are associated with
he interpretation of registry data. Despite appropriate
tatistical adjustments, differences in baseline characteristics
r selection criteria that might not have been recorded could
emain. Potential alternative explanations exist for differ-
nces in event curves, for example, multiple selection biases,
uch as unrecognized propensity to use one type of DES
nstead of another in certain patients. It is also a possible
onfounder, although unlikely a systematic one, that pa-
ients with more than 1 type of DES in the coronary arteries
ere included. Ideally we would like to have included
nformation on insulin treatment because this group of
atients with DM may have a more rapid progression of
therosclerosis (3,5). However, this information was not
vailable for the entire time period we studied. It is a
imitation to our study, which covers 2004 to 2008, that data
n stent thrombosis in the SCAAR database were not
ntroduced until a late stage in the study period. Therefore,
elevant data for stent thrombosis were not available for
ost of the study period.
onclusions
e conclude that the rate of restenosis with DES is higher
n patients with DM compared with that in patients without
M. There seem to be important differences between differ-
nt brands of DES. Our findings reinforce the need of large
rospective randomized trials with head-to-head comparisons
etween different DES, especially in patients with DM.
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